Published in J Cancer on May 01, 2011
Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer. Int J Cancer (2013) 0.99
Incidence of malignancy after living kidney transplantation: a multicenter study from iran. J Cancer (2012) 0.89
Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ. Expert Rev Mol Diagn (2013) 0.88
Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network. Eur J Cancer (2013) 0.88
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol (2013) 0.86
Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients. PLoS One (2014) 0.85
RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target. PLoS One (2012) 0.84
Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer (2013) 0.84
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat (2013) 0.84
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer (2015) 0.82
Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. Breast Cancer Res (2014) 0.82
Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer (2015) 0.81
Regression of ductal carcinoma in situ after treatment with acupuncture. J Altern Complement Med (2013) 0.81
Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast. J Histochem Cytochem (2015) 0.81
Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Breast Cancer Res (2015) 0.81
DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res (2013) 0.81
Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery? Springerplus (2014) 0.81
Priming cancer cells for drug resistance: role of the fibroblast niche. Front Biol (Beijing) (2014) 0.80
Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer (2013) 0.79
Opportunities for molecular epidemiological research on ductal carcinoma in-situ and breast carcinogenesis: interdisciplinary approaches. Breast Dis (2014) 0.78
Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers. Geburtshilfe Frauenheilkd (2014) 0.77
Lattice-based model of ductal carcinoma in situ suggests rules for breast cancer progression to an invasive state. PLoS Comput Biol (2014) 0.77
Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study. Cancer Epidemiol (2012) 0.77
Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. Mod Pathol (2015) 0.77
Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ. Clinics (Sao Paulo) (2013) 0.77
Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). J Breast Health (2013) (2014) 0.75
Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. Breast Cancer Res (2015) 0.75
The hallmarks of premalignant conditions: a molecular basis for cancer prevention. Semin Oncol (2015) 0.75
Ductal carcinoma in situ of the breast: correlation between histopathological features and age of patients. Diagn Pathol (2014) 0.75
Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol (2015) 0.75
Computer-aided heterogeneity analysis in breast MR imaging assessment of ductal carcinoma in situ: Correlating histologic grade and receptor status. J Magn Reson Imaging (2017) 0.75
DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer (2017) 0.75
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst (2010) 4.57
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer (2007) 4.44
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res (2008) 2.69
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst (2010) 2.59
Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) (2009) 2.28
Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol (2007) 2.12
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol (2006) 1.96
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer (2004) 1.59
The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J Surg (2006) 1.49
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res (2005) 1.49
Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J (2009) 1.47
HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol (2002) 1.35
Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia (1998) 1.33
Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer (2001) 1.33
p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia (2004) 1.31
Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer (2001) 1.31
Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer (2003) 1.27
EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat (2003) 1.24
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer (2001) 1.22
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer (2006) 1.18
Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer (2007) 1.17
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res (2005) 1.15
Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer (2006) 1.13
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer (2010) 1.11
Cyclins and breast cancer. Breast Cancer Res Treat (1998) 1.08
Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev (2002) 1.06
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol (2008) 1.04
High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol (2004) 1.01
Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer (2003) 1.00
Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int (2001) 0.99
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer (2010) 0.99
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer (2009) 0.99
Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol (2001) 0.96
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology (2005) 0.96
Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann N Y Acad Sci (2003) 0.95
Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol (2010) 0.95
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology (2004) 0.94
Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res (2002) 0.94
HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol (2005) 0.90
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res (2010) 0.89
Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther (2010) 0.89
Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. J Am Coll Surg (2005) 0.86
Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers. Surgery (2001) 0.86
p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res (2007) 0.85
Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS One (2010) 0.85
COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer (2008) 0.85
Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study. Acta Gastroenterol Belg (2007) 0.85
p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence. Pathol Int (2007) 0.84
Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. Clin Chim Acta (2009) 0.84
The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.83
Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. Anal Quant Cytol Histol (2001) 0.82
Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome. Eur J Obstet Gynecol Reprod Biol (2010) 0.82
Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. BMC Cancer (2008) 0.81
Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas--a preliminary study. Eur J Cancer (2003) 0.81
Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. Isr Med Assoc J (2010) 0.80
Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast. Anticancer Res (2002) 0.80
Rational individualised selection of adjuvant therapy for ductal carcinoma in situ. Lancet Oncol (2010) 0.80
Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev (1998) 0.79
Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Pathol Oncol Res (2000) 0.78
Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients. Pathol Oncol Res (2008) 0.77
Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53. Arch Med Res (2007) 0.76
Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol (2012) 4.44
Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol (2008) 3.49
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics (2005) 2.81
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ (2002) 2.53
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol (2012) 2.40
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer (2003) 2.29
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol (2006) 2.23
Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer (2002) 2.21
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol (2008) 2.17
Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg (2011) 2.16
Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol (2010) 2.12
Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plast Reconstr Surg (2016) 2.05
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol (2004) 2.00
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol (2011) 1.93
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol (2007) 1.92
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg (2009) 1.89
Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem (2003) 1.88
Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg (2007) 1.86
Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg (2003) 1.81
A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. Plast Reconstr Surg (2008) 1.81
Determining the optimal approach to breast reconstruction after partial mastectomy. Plast Reconstr Surg (2006) 1.80
Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol (2003) 1.74
Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol (2008) 1.71
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg (2002) 1.70
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg (2006) 1.70
Delayed-immediate breast reconstruction. Plast Reconstr Surg (2004) 1.66
Advances in breast conservation therapy. J Clin Oncol (2005) 1.64
Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol (2014) 1.63
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol (2004) 1.61
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg (2005) 1.61
Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer (2007) 1.54
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol (2004) 1.52
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys (2002) 1.51
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.51
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer (2005) 1.50
A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. Plast Reconstr Surg (2011) 1.48
Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol (2010) 1.45
Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol (2003) 1.45
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol (2011) 1.44
Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg (2011) 1.42
Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. Plast Reconstr Surg (2017) 1.39
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer (2007) 1.38
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) (2010) 1.35
The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer (2008) 1.35
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol (2002) 1.33
Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg (2003) 1.33
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol (2005) 1.33
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer (2007) 1.32
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol (2012) 1.29
Small (< or = 2-cm) breast cancer treated with US-guided radiofrequency ablation: feasibility study. Radiology (2004) 1.29
Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg (2002) 1.25
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol (2004) 1.25
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol (2002) 1.20
Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat (2005) 1.20
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.20
Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg (2005) 1.20
Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist (2007) 1.19
The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer (2004) 1.18
Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer (2004) 1.18
Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol (2007) 1.18
Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer (2010) 1.18
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys (2007) 1.17
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg (2007) 1.16
Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer (2009) 1.16
Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer (2004) 1.16
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg (2015) 1.15
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg (2009) 1.13
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer (2004) 1.12
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res (2005) 1.12
The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol (2012) 1.12
Advances and surgical decision-making for breast reconstruction. Cancer (2006) 1.10
Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg (2012) 1.10
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer (2008) 1.10
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg (2012) 1.09
Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol (2011) 1.08
Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol (2003) 1.08
Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer (2005) 1.08
Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. Am J Surg (2009) 1.08
Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg (2006) 1.07
Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J (2002) 1.07
A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg (2004) 1.05
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg (2011) 1.05
Breast ductal secretions: clinical features, potential uses, and possible applications. Cancer Control (2007) 1.05
Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer (2006) 1.05
Breast conservation after neoadjuvant chemotherapy. Cancer (2005) 1.04
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer (2004) 1.03
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg (2006) 1.03
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol (2002) 1.02